Trial
Lp(a)FRONTIERS APHERESIS
Status Completed, published July 2026
51 German patients with Lp(a) above 60 mg/dL and established cardiovascular disease on weekly lipoprotein apheresis were randomised to pelacarsen 80 mg or placebo every 4 weeks for 52 weeks; apheresis was performed only if Lp(a) stayed above 60 mg/dL. Pelacarsen reduced the rate of apheresis sessions from 0.93 to 0.16 of the weekly schedule, with a median 6.1 weeks to apheresis avoidance and a 72 percent placebo-adjusted Lp(a) reduction at week 52 (Parhofer et al., EHJ 2026). The first phase 3 result for any Lp(a)-specific drug.
Primary endpoint: rate of performed apheresis sessions normalised to the weekly schedule; secondary: time to apheresis avoidance for 24 consecutive weeks and total avoidance from week 12 to 52. Adverse events were similar between arms apart from mostly mild injection-site erythema (38.5 percent vs 0). Patients rolled into an open-label extension (NCT05900141).
Page updated 17 August 2026.